Background: Globally, the incidence of prostate cancer is estimated to increase by approximately 80% by 2040 compared to 2018. Bone is the most common metastatic site in prostate cancer and accurate prediction of bone metastasis in prostate cancer is crucial for deciding treatment decisions. The aim of this study is to evaluate the potential of G6PD activity level as a biomarker for predicting bone metastasis in patients with prostate cancer.Methods: A total of 56 patients participated in this study and participants included in the study were prostate cancer patients aged 19 years or older who visited YCH Hospital. We compared G6PD activity levels according to presence of bone metastasis. Also, ROC analysis was conducted to evaluate the predictive performance of G6PD activity level for bone metastasis. Optimal cutoff value of G6PD activity level was determined using Youden’s index and corresponding sensitivity and specificity were calculated.Results: The median G6PD activity was significantly higher in the group with bone metastasis than in the group without bone metastasis. According to ROC curve analysis, the area under the curve (AUC) was 0.78 (95% CI, 0.66–0.90). The optimal cutoff value of G6PD activity level for predicting bone metastasis was determined to be 11.5 U/g Hb. At this cutoff value, sensitivity and specificity were 0.81 and 0.73, respectively.Conclusions: G6PD activity is a complementary non-invasive biomarker for predicting bone metastasis in patients with prostate cancer.
背景：全球范围内，预计到2040年，前列腺癌的发病率将较2018年增长约80%。骨骼是前列腺癌最常见的转移部位，准确预测前列腺癌骨转移对治疗决策至关重要。本研究旨在评估G6PD活性水平作为预测前列腺癌患者骨转移生物标志物的潜力。 方法：本研究共纳入56例患者，参与者为年龄≥19岁且在YCH医院就诊的前列腺癌患者。我们根据是否存在骨转移比较了G6PD活性水平。同时，通过ROC分析评估G6PD活性水平对骨转移的预测效能。采用约登指数确定G6PD活性水平的最佳截断值，并计算相应的敏感度和特异度。 结果：骨转移组患者G6PD活性中位数显著高于非骨转移组。ROC曲线分析显示曲线下面积（AUC）为0.78（95% CI：0.66-0.90）。预测骨转移的G6PD活性水平最佳截断值为11.5 U/g Hb，此时敏感度为0.81，特异度为0.73。 结论：G6PD活性可作为预测前列腺癌患者骨转移的补充性无创生物标志物。
肿瘤(癌症)患者之家